Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience
Katsunori Manaka(The University of Tokyo), Noriko Makita(University of Occupational and Environmental Health Japan), Nobuaki Ito(University of Tokyo Hospital), Taroh Iiri(St. Marianna University School of Medicine), Yuka Kinoshita(University of Tokyo Hospital), Junichiro Sato(Kyushu University), Megumi Fujita(Chiba University), Masaomi Nangaku(The University of Tokyo)
Cited by 10
Related Papers
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
|Calcified Tissue International|2019|160
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2017|149
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment
|Endocrine Reviews|2018|148
Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation
|Proceedings of the National Academy of Sciences|2019|147